Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the pharmaceu ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the pharmaceutical company Ferrer, gathered over 150 experts in pulmonology and ca ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

This designation would improve access to specialized treatment for patients across the state. “Pulmonary hypertension remains an underrecognized condition, yet it profoundly impacts patient ...